SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-040222
Filing Date
2023-11-29
Accepted
2023-11-29 16:10:57
Documents
14
Period of Report
2023-11-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20231129.htm   iXBRL 8-K 30290
2 EX-99.1 arwr-20231129x8kex991.htm EX-99.1 68408
6 GRAPHIC ghvnqo5ppwcq000001.jpg GRAPHIC 49974
  Complete submission text file 0001628280-23-040222.txt   306654

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20231129.xsd EX-101.SCH 1931
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20231129_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20231129_pre.xml EX-101.PRE 13066
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20231129_htm.xml XML 2926
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

IRS No.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 231452311
SIC: 2834 Pharmaceutical Preparations